

We claim:

1. A method of treating a disease or disorder in a subject in need thereof comprising:
 - a) identifying the subject as a responder to treatment with at least one SMARCA2/4 degraders via the steps of:
 - 5 i. isolating a biological sample from the subject;
 - ii. determining the presence of tumor specific alterations;
 - iii. identifying the subject as a responder to said treatment if at least one of the tumor specific alterations is present; and
 - b) administering a therapeutically effective amount of at least one SMARCA2/4 degrader
 - 10 to the subject who is identified to respond to the treatment, thereby treating the disease or disorder.
2. The method of claim 1, wherein

the subject is identified as a moderate responder to the treatment with the SMARCA2/4 degraders if one tumor specific alteration is present; or


15 the subject is identified as a high responder to the treatment with the SMARCA2/4 degraders if at least two tumor specific alterations are present.
3. The method of any one of claims 1 to 2, wherein the tumor specific alteration is:

a mutation, an amplification, or an overexpression of Androgen

20 Receptor (AR) gene;

a loss of function or a deleterious mutation in phosphatase and tensin homolog (PTEN); or

a genomic rearrangement that results in a translocation between a TMPRSS2 gene and an ERG gene.
- 25 4. The method of claim 1 or 2, wherein the SMARCA2/4 degrader is a compound of formula (I):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;


wherein,

R₁ is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, -COOR_a, -CON(R_a)₂, or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino, -ONa, -COOR_a, or -OCOR_a; wherein R_a at each occurrence is hydrogen or alkyl;

- 5 R₂ is -NR₃R₄ or -OR₃; wherein, R₃ and R₄ are independently hydrogen or alkyl;

Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

L is a linker with a chemical structure of:



wherein,


the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

R_b is hydrogen or alkyl;

R_c is alkyl;

- 20 'n' is 0 to 10 and 'p' is 1 to 5;

Targeting Ligand (TL) is




wherein,

R_6 is hydrogen, alkyl, acyl, or haloalkyl;

R_7 is $-O-R_5$ or halo; wherein R_5 is hydrogen, alkyl, acyl, or Na; and


5 R_8 is hydrogen or alkyl.

5. The method of claim 4, wherein the SMARCA2/4 degrader is a compound of formula (IA):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

10 6. The method of claim 4, wherein the SMARCA2/4 degrader is a compound of formula (IB):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

15 7. The method of claim 4, wherein the SMARCA2/4 degrader is a compound of formula (IC):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

8. The method of claim 12, wherein the SMARCA2/4 degrader is a compound of formula (D):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

- 5 9. The method of claim 1, wherein the disease is a prostate disease.
10. The method of claim 9, wherein the prostate disease is a prostate cancer.
11. The method of claim 10, wherein the prostate cancer is a castration-resistant prostate cancer.
12. The method of claim 1, wherein the subject has undergone castration.
- 10 13. The method of claim 1, wherein the subject has undergone anti-androgen therapy.
14. A method of selecting a patient with prostate cancer for treatment with a SMARCA2/4 degrader, comprising:
- a) isolating a biological sample from the patient;
 - 15 b) determining a presence of at least one tumor specific alteration in the biological sample; and
 - c) selecting the patient with at least one tumor specific alteration present in the sample for the treatment with the SMARCA2/4 degrader; and
 - d) administering a therapeutically effective amount of at least one SMARCA2/4
 - 20 degrader to the selected patient.
15. The method of claim 14, wherein the tumor specific alteration is:
- a mutation, an amplification, or an overexpression of Androgen Receptor (AR) gene;
 - a loss of function or a deleterious mutation in phosphatase and tensin homolog (PTEN); or
 - 25 a genomic rearrangement that results in a translocation between a TMPRSS2 gene and an ERG gene.

16. The method of claim 14, wherein the SMARCA2/4 degrader is a compound of formula (I):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;


5 wherein,

R₁ is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, -COOR_a, -CON(R_a)₂, or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino, -ONa, -COOR_a, or -OCOR_a; wherein R_a at each occurrence is hydrogen or alkyl;

10 R₂ is -NR₃R₄ or -OR₃; wherein, R₃ and R₄ are independently hydrogen or alkyl;

Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

L is a linker with a chemical structure of:



20 wherein,


the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

R_b is hydrogen or alkyl;

R_c is alkyl;

5 'n' is 0 to 10 and 'p' is 1 to 5;

Targeting Ligand (TL) is:




wherein,

R_6 is hydrogen, alkyl, acyl, or haloalkyl;

10 R_7 is $-O-R_5$ or halo; wherein R_5 is hydrogen, alkyl, acyl, or Na; and


R_8 is hydrogen or alkyl.

17. The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (IA):




15 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

18. The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (IB):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

19. The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (IC):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

20. The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (ID):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

21. The method of claim 14, wherein the prostate cancer is a castration-resistant prostate cancer.

22. The method of claim 14, wherein the patient has undergone castration or anti-androgen therapy.

23. A method of inhibiting proliferation of prostate cancer cells in a subject in need thereof, comprising a step of contacting the prostate cancer cells with at least one SMARCA2/4 degrader.

24. The method of claim 23, wherein the step of contacting comprises administering a therapeutically effective amount of at least one SMARCA2/4 degrader to the subject.

25. The method of any one of claims 23 to 24, wherein the SMARCA2/4 degrader is a compound of formula (I):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
wherein,

R₁ is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, -COOR_a, -CON(R_a)₂, or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino, -ONa, -COOR_a, or -OCOR_a; wherein R_a at each occurrence is hydrogen or alkyl;

- 5 R₂ is -NR₃R₄ or -OR₃; wherein, R₃ and R₄ are independently hydrogen or alkyl;

Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

L is a linker with the chemical structure of:



wherein,


the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

R_b is hydrogen or alkyl;

R_c is alkyl;

- 20 'n' is 0 to 10 and 'p' is 1 to 5;

Targeting Ligand (TL) is:






wherein,

R_6 is hydrogen, alkyl, acyl, or haloalkyl;

R_7 is $-O-R_5$ or halo; wherein R_5 is hydrogen, alkyl, acyl, or Na; and

5 R_8 is hydrogen or alkyl.

26. The method of claim 25, wherein SMARCA2/4 degrader is a compound of formula (IA), (IB), (IC) or (ID):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

27. The method of claim 23, wherein the prostate cancer cells comprise a castration-resistant prostate cancer.

15 28. The method of claim 23, wherein the prostate cancer cells comprise a prostate tumor.







29. The method of claim 23, wherein the subject has undergone castration.







30. The method of claim 23, wherein the subject has undergone anti-androgen therapy.

31. The method of any one of claims 1 to 30, wherein the SMARCA2/4 degrader is a compound with the chemical structure of:






Compound No	Structure
1.	 ;
2.	 ;
3.	 ;

4.	 ;
5.	 ;
6.	 ;
7.	 ;
8.	 ;
9.	 ;





10.	
11.	
12.	
13.	
14.	
15.	






16.	
17.	
18.	
19.	
20.	
21.	






22.	<chem>Nc1cc(O)c2ccccc2n1N3CCN(CC3)NC(=O)CCCCCCCCC(=O)N[C@@H]4C[C@H](C)[C@@H](C)[C@H]4C(=O)N[C@@H]5C[C@H](Cc6ccc(cc6)sc7c[nH]c7)c5O</chem> ;
23.	<chem>Nc1cc(O)c2ccccc2n1N3CCN(CC3)NC(=O)CCCCCCCCC(=O)N[C@@H]4C[C@H](C)[C@@H](C)[C@H]4C(=O)N[C@@H]5C[C@H](Cc6ccc(cc6)sc7c[nH]c7)c5O</chem> ;
24.	<chem>Nc1cc(O)c2ccccc2n1N3CCN(CC3)NC(=O)CCCCCCCCC(=O)N[C@@H]4C[C@H](C)[C@@H](C)[C@H]4C(=O)N[C@@H]5C[C@H](Cc6ccc(cc6)sc7c[nH]c7)c5O</chem> ;
25.	<chem>Nc1cc(O)c2ccccc2n1N3CCN(CC3)NC(=O)CCCCCCCCC(=O)N[C@@H]4C[C@H](C)[C@@H](C)[C@H]4C(=O)N[C@@H]5C[C@H](Cc6ccc(cc6)sc7c[nH]c7)c5O</chem> ;
26.	<chem>Nc1cc(O)c2ccccc2n1N3CCN(CC3)NC(=O)CCCCCCCCC(=O)N[C@@H]4C[C@H](C)[C@@H](C)[C@H]4C(=O)N[C@@H]5C[C@H](Cc6ccc(cc6)sc7c[nH]c7)c5O</chem> ;
27.	<chem>Nc1cc(O)c2ccccc2n1N3CCN(CC3)NC(=O)CCCCCCCCC(=O)N[C@@H]4C[C@H](C)[C@@H](C)[C@H]4C(=O)N[C@@H]5C[C@H](Cc6ccc(cc6)sc7c[nH]c7)c5O</chem> ;






28.	 ;
29.	 ;
30.	 ;
31.	 ;
32.	 ;





33.	<chem>CC1=NC=C(C=C1)SC2=CC=C(C=C2)NC(=O)[C@H]3CC[C@@H](C3)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCCC(=O)N4CCN(CC4)C5=CC=C(C=C5)N6C=CC(=C6)N=C5N</chem> ;
34.	<chem>CC1=NC=C(C=C1)SC2=CC=C(C=C2)NC(=O)[C@H]3CC[C@@H](C3)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCCCCC(=O)N4CCN(CC4)C5=CC=C(C=C5)N6C=CC(=C6)N=C5N</chem> ;
35.	<chem>CC1=NC=C(C=C1)SC2=CC=C(C=C2)NC(=O)[C@H]3CC[C@@H](C3)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCCCCCC(=O)N4CCN(CC4)C5=CC=C(C=C5)N6C=CC(=C6)N=C5N</chem> ;
36.	<chem>CC1=NC=C(C=C1)SC2=CC=C(C=C2)NC(=O)[C@H]3CC[C@@H](C3)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCC(=O)N4CCN(CC4)C5=CC=C(C=C5)N6C=CC(=C6)N=C5N</chem> ;





37.	 ;
38.	 ;
39.	 ;
40.	 ;

41.	 ;
42.	 ;
43.	 ;
44.	 ;
45.	 ;






46.	 ;
47.	 ;
48.	 ;
49.	 ;
50.	 ;






51.	 ;
52.	 ;
53.	 ;
54.	 ;
55.	 ;





56.	
57. and 58.	 Isomer-1 and Isomer-2
59.	
60.	






61.	
62.	
63.	
64.	

65.	<chem>CC1(C)C(C(=O)N[C@@H](C1)C[C@H](O)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCN2CCN(C2)c3cc(N)nnc3c4ccccc4O)C5=CC=C(C=C5)C6=CC=CC=C6N7C=CC(=C7)S8C=CC(=C8)C</chem> ;
66.	<chem>CC1(C)C(C(=O)N[C@@H](C1)C[C@H](O)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCN2CCN(C2)c3cc(N)nnc3c4ccccc4O)C5=CC=C(C=C5)C6=CC=CC=C6N7C=CC(=C7)S8C=CC(=C8)C</chem> ;
67.	<chem>CC1(C)C(C(=O)N[C@@H](C1)C[C@H](O)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCN2CCN(C2)c3cc(N)nnc3c4ccccc4O)C5=CC=C(C=C5)C6=CC=CC=C6N7C=CC(=C7)S8C=CC(=C8)C</chem> ;
68.	<chem>CC1(C)C(C(=O)N[C@@H](C1)C[C@H](O)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCN2CCN(C2)c3cc(N)nnc3c4ccccc4O)C5=CC=C(C=C5)C6=CC=CC=C6N7C=CC(=C7)S8C=CC(=C8)C</chem> ;
69.	<chem>CC1(C)C(C(=O)N[C@@H](C1)C[C@H](O)C(=O)N[C@@H](C(C)(C)C)C(=O)NCCN2CCN(C2)c3cc(N)nnc3c4ccccc4O)C5=CC=C(C=C5)C6=CC=CC=C6N7C=CC(=C7)S8C=CC(=C8)C</chem> ;





70.	
71.	
72.	
73.	
74.	

75.	
76.	
77. and 78.	 Isomer-1 and Isomer-2
79.	
80.	

81.	 ;
82.	 ;
83. and 84.	 Isomer-1 and Isomer-2 ;
85.	 ;






86.	
87.	
88.	
89.	
90.	






91.	<chem>Cc1nc(Cc2ccc(cc2)C[C@H](C)C(=O)N[C@@H](C(C)(C)C)C(=O)N3CC[C@H](O)C3)c(C)s1C4=CC=C(C=C4)C5=CC(=CC=C5)C(=N5C=CC(=N5)N)C(=N6C=CC(=C6)O)N</chem> ;
92.	<chem>Cc1nc(Cc2ccc(cc2)C[C@H](C)C(=O)N[C@@H](C(C)(C)C)C(=O)N3CC[C@H](O)C3)c(C)s1C4=CC=C(C=C4)C5=CC(=CC=C5)C(=N6C=CC(=N6)N)C(=N7C=CC(=C7)C(=O)O)N</chem> ;
93.	<chem>Cc1nc(Cc2ccc(cc2)C[C@H](C)C(=O)N[C@@H](C(C)(C)C)C(=O)N3CC[C@H](O)C3)c(C)s1C4=CC=C(C=C4)C5=CC(=CC=C5)C(=N6C=CC(=N6)N)C(=N7C=CC(=C7)N)N</chem> ;
94.	<chem>Cc1nc(Cc2ccc(cc2)C[C@H](C)C(=O)N[C@@H](C(C)(C)C)C(=O)N3CC[C@H](O)C3)c(C)s1C4=CC=C(C=C4)C5=CC(=CC=C5)C(=N6C=CC(=N6)N)C(=N7C=CC(=C7)C(=O)O)F</chem> ;
95.	<chem>Cc1nc(Cc2ccc(cc2)C[C@H](C)C(=O)N[C@@H](C(C)(C)C)C(=O)N3CC[C@H](O)C3)c(C)s1C4=CC=C(C=C4)C5=CC(=CC=C5)C(=N6C=CC(=N6)N)C(=N7C=CC(=C7)C(=O)O)N</chem> ;


96.	
97.	
98.	
99.	

100.	 ;
101.	 ;
102.	 ;
103.	 ;

104.	 ;
105.	 ;
106.	 ;
107.	 ;

108.	 ;
109.	 ;
110.	 ;
111.	 ;
112.	 ;

113.	 ;
114.	 ;
115.	 ;
116.	 ;
117.	 ; or



or a pharmaceutically acceptable salt or a stereoisomer thereof.

32. A method of selecting a subject with prostate disease for treatment with a SMARCA2/4 degrader, comprising:

- a) isolating a biological sample from the subject;
- 5 b) determining a presence of at least one tumor specific alteration in the biological sample;
- c) selecting the patient with at least one tumor specific alteration present in the sample for the treatment with the SMARCA2/4 degrader; and
- 10 d) administering a therapeutically effective amount of at least one SMARCA2/4 degrader to the selected subject.

33. The method of claim 32, wherein the tumor specific alteration is:

- a mutation, an amplification, or an overexpression of Androgen Receptor (AR) gene;
- a loss of function or a deleterious mutation in phosphatase and tensin homolog (PTEN); or
- 15 a genomic rearrangement that results in a translocation between a TMPRSS2 gene and an ERG gene.

34. The method of claim 32, wherein SMARCA2/4 degrader is a compound of formula (I):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;


wherein,

R₁ is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, -COOR_a, -CON(R_a)₂, or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino, -ONa, -COOR_a, or -OCOR_a; wherein R_a at each occurrence is hydrogen or alkyl;

- 5 R₂ is -NR₃R₄ or -OR₃; wherein, R₃ and R₄ are independently hydrogen or alkyl;

Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

L is a linker with a chemical structure of:



wherein,


the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

R_b is hydrogen or alkyl;

R_c is alkyl;

- 20 'n' is 0 to 10 and 'p' is 1 to 5;

Targeting Ligand (TL) is:






wherein,

R_6 is hydrogen, alkyl, acyl, or haloalkyl;

R_7 is $-O-R_5$ or halo; wherein R_5 is hydrogen, alkyl, acyl, or Na; and

5 R_8 is hydrogen or alkyl.

35. The method of claim 34, wherein SMARCA2/4 degrader is a compound of formula (IA), (IB), (IC) or (ID):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

36. The method of claim 32, wherein the prostate disease is a prostate cancer.

37. The method of claim 32, wherein the prostate cancer is a castration-resistant prostate cancer.

38. The method of claim 32, wherein the subject has undergone castration.

39. The method of claim 32, wherein the subject has undergone anti-androgen therapy.

40. A compound for use in method of selecting the subject with prostate cancer wherein the compound is represented by compound of formula (I):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;


wherein,


R_1 is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, $-\text{COOR}_a$, $-\text{CON}(\text{R}_a)_2$, or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino, $-\text{ONa}$, $-\text{COOR}_a$, or $-\text{OCOR}_a$; wherein R_a at each occurrence is hydrogen or alkyl;

R_2 is $-\text{NR}_3\text{R}_4$ or $-\text{OR}_3$; wherein, R_3 and R_4 are independently hydrogen or alkyl;

Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

L is a linker with a chemical structure of:





wherein,


the left side of the linker is attached with ring A and the right side of the linker
5 is attached with Targeting Ligand (TL);

R_b is hydrogen or alkyl;

R_c is alkyl;

'n' is 0 to 10 and 'p' is 1 to 5;

Targeting Ligand (TL) is




wherein,

R_6 is hydrogen, alkyl, acyl, or haloalkyl;

R_7 is $-O-R_5$ or halo; wherein R_5 is hydrogen, alkyl, acyl, or Na; and


R_8 is hydrogen or alkyl.

15 41. The compound for use according to claim 40, wherein the compound is represented by compound of formula (IA):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

42. The compound for use according to claim 40, wherein the compound is represented by compound of formula (IB):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

5 43. The compound for use according to claim 40, wherein the compound is represented by compound of formula (IC):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

44. The compound for use according to claim 40, wherein the compound is
10 represented by compound of formula (ID):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.